Λογότυπο www.galinos.gr Beta
 

Ιατροφαρμακευτική πληροφόρηση για τον επαγγελματία υγείας

Φάρμακα Δραστικές ουσίες Συμπληρώματα διατροφής Έλεγχος συγχορήγησης Νόσοι ICD-10
Κλαύδιος Γαληνός
Είσοδος χρηστών
Όνομα χρήστη
Συνθηματικό
Εικονίδιο Είσοδος χρήστη
Εικονίδιο Δωρεάν εγγραφή
Εικονίδιο Ανανέωση συνθηματικού

Ακολουθήστε μας Λογότυπο Facebook Λογότυπο Twitter

Αναζήτηση σε 63811 καταχωρήσεις
Εικονίδιο αναζήτησης

Βιβλιογραφική αναφορά

Προτάσεις

SPC, UK: Evoltra 1mg/ml concentrate for solution for infusion (2011)

Εκδότης

Εκδότης SANOFI
Διεύθυνση 1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Σφάλμα Για την προβολή της πλήρους καταχώρησης χρειάζεται να έχετε συνδρομή σε ισχύ (αγορά συνδρομής).
Ολοκληρώνοντας τη διαδικασία δωρεάν εγγραφής θα αποκτήσετε, χωρίς καμία δέσμευση εκ μέρους σας, συνδρομή διάρκειας 30 ημερών.

Περιεχόμενα

Name of the medicinal product

Evoltra 1 mg/ml concentrate for solution for infusion.

Qualitative and quantitative composition

Each ml of concentrate contains 1 mg of clofarabine. Each 20 ml vial contains 20 mg of clofarabine. ...

Pharmaceutical form

Concentrate for solution for infusion. Clear, practically colourless solution with a pH of 4.5 to 7.5 ...

Therapeutic indications

Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory ...

Posology and method of administration

Therapy must be initiated and supervised by a physician experienced in the management of patients with ...

Contraindications

Hypersensitivity to clofarabine or to any of the excipients (see section 6.1). Use in patients with severe ...

Special warnings and precautions for use

Evoltra is a potent antineoplastic agent with potentially significant haematological and non-haematological ...

Interaction with other medicinal products and other forms of interaction

No formal interaction studies have been performed to date with clofarabine. However, there are no known ...

Fertility, pregnancy and lactation

Contraception in males and females Females of childbearing potential and sexually active males must use ...

Effects on ability to drive and use machines

No studies on the effects of clofarabine on the ability to drive and use machines have been performed. ...

Undesirable effects

The information provided is based on data generated from clinical trials in which 115 patients (> 1 and ...

Overdose

No case of overdose has been reported. However, possible symptoms of overdose are expected to include ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, antimetabolites ATC code: L01BB06 Mechanism of action: ...

Pharmacokinetic properties

The pharmacokinetics of clofarabine were studied in 40 patients aged between 2 to 19 years old with relapsed ...

Preclinical safety data

Toxicology studies of clofarabine in mice, rats and dogs showed that rapidly proliferating tissues were ...

List of excipients

Sodium chloride Water for injections

Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section ...

Shelf life

3 years. The diluted concentrate is chemically and physically stable for 3 days at 2°C to 8°C and at ...

Special precautions for storage

Do not freeze. For storage conditions of the diluted medicinal product, see section 6.3.

Nature and contents of container

Type I glass vial with bromobutyl rubber stopper, polypropylene flip-off cap and aluminium overseal. ...

Special precautions for disposal and other handling

Evoltra 1 mg/ml concentrate for solution for infusion must be diluted prior to administration. It should ...

Marketing authorization holder

Genzyme Europe BV Gooimeer 10 1411DD Naarden The Netherlands Tel: +31 (0)35 699 12 00 Fax: +31 (0) 35 ...

Marketing authorization number(s)

EU/1/06/334/001 3 vials EU/1/06/334/002 4 vials EU/1/06/334/003 10 vials EU/1/06/334/004 20 vials EU/1/06/334/005 ...

Date of first authorization / renewal of the authorization

Date of first authorisation: 29 May 2006 Date of latest renewal: 24 March 2011

Date of revision of the text

11/2011
Απαγορεύεται η αναπαραγωγή και αναδιανομή. Το έργο επεξεργασίας των παραπάνω πληροφοριών αποτελεί πνευματική ιδιοκτησία της Ergobyte Πληροφορική Α.Ε. και προστατεύεται από τη νομοθεσία περί πνευματικών δικαιωμάτων.